



Evaluation of the Feasibility and Validity of Short Message System (SMS) Text Messaging for Assessment of Antiretroviral Therapy Adherence among Youth Living with HIV/AIDS (YLH)

Nadia Dowshen, MD
Lisa Kuhns, PhD, MPH
Camdin Gray, BA
Susan S. Lee, BA
Amy Johnson, MSW
Robert Garofalo, MD, MPH



Disclosures

- Nadia Dowshen, MD has documented that her presentation will not involve discussion of unapproved or off label, experimental or investigational use.
- Nadia Dowshen, MD has no financial relationships to disclose or conflicts of interest (COIs) to resolve.

The HIV Epidemic among Youth in the United States

- Over 1 million people in the US living with HIV/AIDS
- Approximately 50,000 new infections each year
- Large portion of new infections occurring among youth, mainly through sexual contact
- Many perinatally infected individuals now surviving to adulthood

Antiretroviral Adherence

- High level of adherence required for optimal health outcomes
- Associated risk factors for poor adherence include
 - Depression
 - Stigma
 - Substance abuse
- Reasons cited for poor adherence include
 - Pill burden/frequency
 - Side effects
 - Stigma/Privacy
 - Simply forgetting

Adherence Interventions

- Directly observed therapy (DOT)
- Phone call reminders
- Regular counseling

The Challenge of Measuring Adherence

- Current methods
 - Self report
 - Pharmacy refill
 - Drug levels
 - Electronic drug monitoring
- Strengths and weaknesses
 - Variability in correlation with biologic outcomes
 - Cost and practicality

Short Message System (SMS) Technology

- 331 million cell phones in use and 7 billion text messages sent every month
- common mode of communication among all youth
- may increase adherence among children and adolescents living with other chronic diseases
- Technology offers opportunity to both intervene on and assess adherence in real time

Hypotheses

- Interactive text message response (ITR) to measure adherence will be feasible and acceptable for HIV-positive youth.
- ITR rates will correlate with the validated VAS adherence measure.
 - —
 ûduring the first 12 weeks
 - —
 ûduring weekdays

Study Participation

- Eligibility Criteria
 - HIV-positive serostatus,
 - Aged 12 -29,
 - Use of personal cell phone,
 - English-speaking
 - On ART with poor adherence
- Enrollment
 - Recruited consecutively from June to November 2009
 - 24-week study period

Measures

- Baseline Measures
 - Demographics
 - Alcohol and Other Drugs (AOD)
 - Brief Symptoms Inventory (BSI)
- Primary Outcome: Satisfaction Survey
- Primary Outcome: Adherence
 - Visual Analog Scale (VAS)
 - AIDS Clinical Trial Group (ACTG) Adherence Questionnaire
 - Interactive text response
- Secondary Outcome: Disease Specific Markers

Intelecare Technology

Program message



Pt receives daily reminder



Message 1 hr later asking whether they have taken meds



Pt sends text back 1= yes, 2= no

User Management

Logged in as : matt@intelecare.com with Howard Brown

▶ Users ▶ Reminders ▶ Logout

Save User Manage 2 Reminders			Reset Password Send Welcome Email
Personal Information		Account Informa	ition
*First Name		Creation Date	2009-06-15 14:08:35
Matthew		Last Activation	2009-06-15
*Last Name		Last Updated	2010-11-17 14:46:09
Pepe		First Reminder	2009-06-15
*Primary/Login Email Address	1	Account Status	Active
matt@intelecare.com	No Login [?]	Admin Expiration	
Additional Email Address(es) + add additional email(s) Phone Number(s)		Survey Tags	
1 (203) 506-0233	Mobile remove	Password	
+ add additional phone number(s)	_	201f00b5ca5d65	Salc118e5e3243151
		Leave the passwor	red as a hash. assword and it will be hashed when saved. ad alone to not change it. Reset' to prompt the user to update their



Save User

CD4 Adherence measures BSI, AOD Adherence Measures Satisfaction survey CD4 Adherence Measures Satisfaction Survey Adherence Measures Satisfaction Survey Adherence Measures CD4

Satisfaction Survey

Data Management

- Database created in Excel which included:
 - phone number for the participant
 - text of the outgoing or incoming message
 - whether it was an outgoing or incoming message
 - date message was sent/received
 - time of day/night the message was sent/received
- Over 15,500 rows of sent/received messages
- Messages sorted by participant and cleaned

Analysis

- Messages successfully sent with appropriate responses from participant were summed
- Interactive text response adherence scores from 0-100% were calculated
- ITR adherence scores on weekday vs. weekend and 0-12 vs. 13-24 weeks were compared using paired t-tests
- Pearson correlations between ITR adherence and VAS scores overall and for each time-period (6, 12, 18, and 24 weeks) were calculated to assess comparability

Sample Characteristics

N=25	Mean or frequency, (SD or %; range)
Age	23 (3.08; 14-29)
Gender	
Male	23 (92%)
Female	2 (8%)
Race/Ethnicity	
Black	15 (60%)
White	2 (8%)
Latino	6 (24%)
Multiracial	2 (8%)

Sample Characteristics

N=25	Mean or frequency, (SD or percentage; range)
Transmission Mode	
Perinatal	3 (12%)
Unprotected sex	21 (84%)
Unsure	1 (4%)
Time since dx (months)	41 (43.4; 7-180)
Time on ART (months)	37 (59.4; 1-240)
Medication frequency	
Daily	20 (80%)
Twice Daily	5 (20%)

ITR and Adherence Rates (n=21 of 25)

- Total texts sent, mean=175 (SD=70.3), range=80 to 387 messages
- Overall response rate= 60.9% (SD= 29.5, range= 6.0% - 99.2%)
- Overall adherence rate= 57.0% (SD= 27.7%, range=6.0% - 94.8%)

ITR adherence rates by study period and week day

Weel	kday	Week		end	
Mean	SD	Mean	SD	P value	
58.3	27.8	54.6	28.5	.07	
Weeks	ks 0-12 Weeks		Veeks 1	L3-24	
58.4	27.4	53.9	34.3	.37	

Correlation of VAS and ITR adherence rates by time period

	6 wk ITR	12 wk ITR	18 wk ITR	24 wk ITR
6 wk VAS	r=.52*			
12 wk VAS		r=.09		
18 wk VAS			r=09	
24 wk VAS				r=14

^{*} p≤.05

Limitations

- Small sample size
- No control group
- No coaching/feedback on ITR provided to participants
- Unable to interpret inappropriate response data
- Generalizability may be limited

Conclusions

- ITR adherence rates were correlated with VAS during the first 6 weeks of the study period
- Larger studies including coaching/feedback on ITR for participants are needed to determine the validity of ITR as an adherence measure
- Non-significant trends in this small sample suggest that ITR can provide important clinical information about adherence patterns during various time periods

Acknowledgements

- Co-Authors
- Howard Brown Health Center/Children's
 Memorial Hospital Youth HIV program Staff for
 their support of this study
- Intelecare for their generous software donation
- Youth who participated in the study

Message Content

Did you forget about rule #3?

Have you taken your pills yet?

Time to take my pills

Nick, take your meds.

Take your vitamins

Your health comes 1st, so take your meds!

Feasibility/Acceptability

N=21	Percentage
Retention rate (N=25)	84%
Helpful to avoid missed doses?	95%
Helpful to remember refills?	76%
Helpful to remember medical appointments?	71%
Messages respected privacy	100%
Received all messages	81%
Would like to continue to receive reminders?	81%
Reminders would have been helpful when starting meds?	100%

Adherence Outcomes

N=21	Mean (baseline)	Mean (24 wks)	P value
VAS	74.7	93.3	<0.01
ACTG	2.33	3.19	<0.01

Disease Specific Outcomes

N=17	Mean (baseline)	Mean (24 wks)	P value
CD4	501	544	0.370
Viral load	2750	28	0.226